Devrim Çabuk
YOU?
Author Swipe
View article: Real-World Evaluation of the HELPP Score and CALLY Index for Preoperative Prognostic Stratification in Resectable Pancreatic Ductal Adenocarcinoma
Real-World Evaluation of the HELPP Score and CALLY Index for Preoperative Prognostic Stratification in Resectable Pancreatic Ductal Adenocarcinoma Open
Background/Objectives: Preoperative prognostic assessment is essential for optimizing treatment strategies in pancreatic ductal adenocarcinoma (PDAC). This study aimed to evaluate and compare the prognostic value of the Heidelberg Pancreat…
View article: How mindfulness and coping styles shape anxiety and depression in metastatic gastrointestinal cancer
How mindfulness and coping styles shape anxiety and depression in metastatic gastrointestinal cancer Open
Objectives Significant psychological distress is prevalent among patients with advanced gastrointestinal cancer, underscoring the need to investigate the roles of mindfulness and coping strategies in shaping emotional outcomes. However, th…
View article: Structural Retinal and Optic Nerve Changes in Prostate Cancer Patients Receiving Androgen Receptor Pathway Inhibitors: An OCT-Based In Vivo Analysis
Structural Retinal and Optic Nerve Changes in Prostate Cancer Patients Receiving Androgen Receptor Pathway Inhibitors: An OCT-Based In Vivo Analysis Open
Objective: To conduct a comparative analysis of layer-by-layer macular thickness, peripapillary retinal nerve fiber layer (pRNFL), and minimum rim width (MRW) between the eyes of patients with prostate cancer undergoing treatment with andr…
View article: Cetuximab-Related Skin Toxicity as a Predictive Marker for Treatment Response and Prognosis in Recurrent/Metastatic Head and Neck Cancer Patients Treated with Cetuximab and Chemotherapy Combination
Cetuximab-Related Skin Toxicity as a Predictive Marker for Treatment Response and Prognosis in Recurrent/Metastatic Head and Neck Cancer Patients Treated with Cetuximab and Chemotherapy Combination Open
Objective: Cetuximab (Cmab)-related skin toxicity is a frequent adverse reaction in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (r/mSCCHN). We wanted to evaluate whether skin toxicity can be used a…
View article: HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy
HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy Open
Aim: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer which represents the most common subgroup of metastatic breast cancer (MBC). Recently, further subclassification for HER2-negative tumors ha…
View article: HALP-H Index as a Prognostic Biomarker for Predicting Pathological Complete Response in Early-Stage HER2-Positive Breast Cancer—A Multicenter Retrospective Cohort Study
HALP-H Index as a Prognostic Biomarker for Predicting Pathological Complete Response in Early-Stage HER2-Positive Breast Cancer—A Multicenter Retrospective Cohort Study Open
Objectives: Inflammation plays an important role in cancer development, and various inflammation parameters are used as potential prognostic markers. This study aimed to evaluate the effectiveness of the combined use of HALP and H index in…
View article: Does Tumor Laterality Influence Response to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer?
Does Tumor Laterality Influence Response to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer? Open
Aim: The prognostic significance of tumor laterality has been explored in various solid malignancies, with varying findings across differ ent cancer types. This study investigated the potential for predicting treatment response rates based…
View article: Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study
Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study Open
Background and Objectives: Early-onset breast cancer (EOBC), particularly in patients under 40, presents with distinct biological characteristics and worse survival outcomes compared to late-onset cases. Despite intensive treatments, EOBC …
View article: A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy Open
To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive …
View article: 223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study
223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study Open
Real-world (RW) data provide valuable information about the effectiveness and safety of treatment modalities in the general population that is not limited by selection criteria in clinical studies. The aim of this study was to evaluate the…
View article: Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review)
Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review) Open
Breast cancer is most frequently diagnosed among women aged 65-74 years and the prevalence of comorbidities in elderly patients with breast cancer is 32.2%. In addition, polypharmacy is quite common in these patients. Understanding the int…
View article: Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu–PSMA-617
Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu–PSMA-617 Open
This study is aimed to investigate the prognostic significance of inflammation indices, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation in…
View article: 252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study
252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study Open
There is limited data on the effect of CDK 4/6 inhibitors in the patients with advanced HR-positive and HER2-low tumors. Here we report real-life data retrospectively collected from 448 patients with ER-positive/HER2-negative advanced brea…
View article: Major and minor salivary gland cancers: A multicenter retrospective study
Major and minor salivary gland cancers: A multicenter retrospective study Open
Background Most of the studies on salivary gland cancers are limited for various reasons such as being single‐center, small number of patients, including only major or minor SGCs, or only including epidemiological data. Methods A total of …
View article: Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer Open
Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast ca…
View article: Gastrointestinal Involvement in a Patient with Chronic Lymphocytic Leukemia
Gastrointestinal Involvement in a Patient with Chronic Lymphocytic Leukemia Open
A 70-year-old man was admitted to the hospital with symptoms of fatigue and dyspnea.
View article: P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey Open
Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK inhibitor. The aim of this study…
View article: The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey
The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey Open
Background: ROS1 mutation occurs in approximately 1-2% of patients with NSCLC. There are limited data on the efficacy of crizotinib therapy in the treatment of ROS1-positive advanced stage NSCLC. The survival results of two studies evaluat…
View article: Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results
Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results Open
Background: Anti-HER2 agents were a breakthrough in the treatment of HER2-enriched breast cancer (BC). In this study, we aimed to describe the real-life efficacy and safety of pertuzumab-trastuzumab-taxane (PTT) combination in BC patients.…
View article: Netrin-1 in cancer: Potential biomarker and therapeutic target?
Netrin-1 in cancer: Potential biomarker and therapeutic target? Open
Netrin-1, a laminin-related protein, is known to be involved in the nervous system development. Recently, Netrin-1’s involvement in other processes such as cell adhesion, motility, proliferation, and differentiation that are important for …
View article: Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas
Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas Open
The primary location, the histological type of sarcomatous and the epithelial component may be predictive factors for the efficacy of chemotherapy or radiotherapy in UCS and OCS.